top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
crossref
doi
open access

Published: 23 August 2019

The Additive Effect of Hepatitis B Virus and Aflatoxin B1 to Liver Disease Burden: A Case Study in Kitui, Makueni and Machakos Counties, Kenya

Pius Mutisya Kimani, Yeri Kombe, Fred W. Wamunyokoli, Charles F. L. Mbakaya, James K. Gathumbi

Institute of Tropical Medicine and Infectious Diseases JKUAT, Center for Public Health Research KEMRI, Jomo Kenyatta University of Agriculture and Technology, Rongo University, University of Nairobi

journal of social and political sciences
pdf download

Download Full-Text Pdf

doi

10.31014/aior.1994.02.03.52

Pages: 312-331

Keywords: Hepatitis B Virus, Aflatoxin B1, Additive Effect to Liver Disease, Kitui, Makueni, Machakos

Abstract

There are various causes of liver disease, including viruses, trauma, and toxins. Hepatitis B virus (HBV) is a major etiological agent for liver disease in lower eastern Kenya. This had compounded an already existing problem of aflatoxinB1 induced hepatoxicity associated with contaminated grain which had been reported over the years in parts of the region including Kitui, Makueni and Machakos counties. A study was carried out to evaluate the additive effects of hepatitis B virus (HBV) and dietary AFB1 in liver disease among the subjects. Liver disease bio markers HBSAg and AFB1 lysine albumen adducts were used in this study. The investigation was conducted as a case-control study where blood samples from appropriately selected subjects were collected and analyzed for exposure to dietary AFB1 and HBV. A non-probability purposive sampling method was used to choose and divide the study area into strata with 19 clusters. The sample size (n) for the human case-control study was determined as per the Schelsselman formula (1982), as 283 each for both cases and controls A computer software SPSS® version 18.0 was used to analyze the data statistically. For case subjects, 52.29% (n=148) of serum samples were positive for HBsAg with level range of 500 to 9800 Iu/mL and a mean of 3.204 х 103 Iu/mL {95%; CI= (2.76 to 3.65)х 103}, p≤ 0.05. For controls, 24% (n=68) of serum sample was positive for HBsAg with a level range of 50 to 990 Iu/mL and a mean of 347.57 Iu/mL (95%; CI= (278.35 to 416.80), p≤ 0.05. For AFB1 lysine albumin adducts, case subjects had 55.83% (n=158) of positive serum sample with a level range of 15.5 to 135.0 pg/mg and a mean of 42.93 pg/mg (95%; CI= (39.36 to 46.51) p≤ 0.05, while the controls with 31.0% (n=88) of positive serum sample had a lower AFB1 serum albumin adducts level range of 3.5 to 60.5 pg/mg with a mean of 14.30 pg/mg (95%; CI= (12.23 to 16.36), p≤ 0.05. Case subjects had higher means for both HBsAg and AFB1 lysine albumin adducts than controls, suggesting an additive effect on liver disease among the subjects. In control subject samples, lower HBsAg suggested either a carrier state or a recent exposure and recovery from HBV. In control serum samples, lower mean AFB1 lysine albumin adducts suggested a lower level of dietary aflatoxin B1 exposure among those subjects. The case and control cohorts, the higher total number of serum samples testing positive for HBsAg, 30.83% (n=175) and AFB1 lysine albumin adducts 36.13% (n=205) out of the total sample (N=566), implied that the causal factors for the liver disease were endemic in the region. There was a higher dietary AFB1 exposure to residents than HBV exposure. It is concluded that AFB1 induced hepatoxicity was more prevalent than HBV infection among the study subjects.

References

  1. Agro food & veterinary diagnostics organization (AVD), (2013). Mycotoxins Handbook: Euroclone kits for mycotoxins detection: www.euroclonegroup.it/allegati/prodotti/flyermycoen/3288/pdf

  2. Bao, L., Trucksess M. W., White K. D. (2010). “Determination of Aflatoxins B1, B2, G1 and G2 in olive oil, peanut oil and sesame oil”. Journal of AOAC international, 93 (3) : 936 –942.

  3. Bell,S.J., Nguyen,T.(2009). “The management of hepatitis B infection.” Australian preser. 23(4):99-104.

  4. Buddeberg, F., Schimmer B., Spahn, D. (2008). Transfusion-transmissible infections and transfusion-related immunomodulation. Best Practice & Research. Clinical Anaesthesiology 22 (3): 503–17.   

  5. Coucil for agriculture, science & technology(CAST). (1989). Mycotoxins: Economics and health risks. Task force report No.116 Ames, IOWA, 1: 5-8.

  6. Chan, H,L., Wonq, G, L., Chin, A, M., Yu, K, K., Chan, H,Y., Sunq, J,J., Wonq, V,W.(2009). Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clinical gastroenterelogy hepatology, 7(12):1361-1366

  7. CDC, ( 2012). Epidemiology and prevention of preventable diseases. The Pink Book: Courses textbook- 12th edition, 9:216--240

  8.  CDC, (2004). Outbreak of aflatoxins poisoning in Eastern and Central provinces, Kenya,–July 2004. Morbidity Mortality Weekly Report. 53: 790 –792.

  9. Chan, H. L., Wong, V.W., Wong, G. L., Tse, C. H., Chan, H. Y., Sung, J. J. (2010): A Longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic Hepatitis B. Journal of hepatology 52:1232-1241.

  10. Chen, D., Kaplan, L.(2006).The performance of a new generation chemiluminescent assay for hepatitis B surface antigen. Clinical chemistry 52:1592--1598

  11. Coffin, C. S., Mulrooney-Cousins, P.M., Vanmarle, G., Roberts, J.P., Michalak, T.I., Terrault, N. (2011). "Hepatitis B virus (HBV) quasispecies in hepatic and-extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy". Liver Transplants, 17 (8): 955–62

  12. Dufour, D.R. (2006).Hepatitis B surface antigen(HBsAg) Assays -- are they Good enough for their current uses?. Clinical chemistry. 52(8): 1447--1458

  13. EFSA, (2013). Aflatoxins in food. www.efsa.europa.eu/en/topics/topic/aflatoxins.htm

  14. Fairley, C., Read, T. (2012). Vaccination against sexually transmitted infections. Current Opinion in Infectious Diseases, 25 (1): 66–72.

  15. Gan, S.I., Devlin, S.M., Scott-Douglss, N.W., Burak, K.W.(2005). “Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection”.  Canadian journal of gastroenterology, 19(10):625-629.

  16. Gathumbi, J.K., Usleber, E., Martlbauver, E.(2001). Production of ultra sensitive antibodies against aflatoxin B1. Letters in applied microbiology, 32:347- 351.

  17. Golthardt, D., Riediger,C., Weis, K.H., Encke,J.,  Schemmer,P., Schmidt,J., Sauer, P. (2009). Fulminant hepatic failure, etiology and indications for liver transplantation. Nephrology dialysis & transplantation, 22(8):85-88.

  18. Iannacone, M., Sitia G, Isogawa, M., Marchese, P., Castro, M., Lowenstein, P., Chisari, F., Ruggeri, Z.,, Guidotti, L. (2005). Platelets mediate cytotoxic T lymphocyte-induced liver damage. National Medical journal, 11 (11): 1167–9.

  19. Karayiannis, P., Thomas, H., Mahy, B., Regenmortel, M. (2009).  Desk Encyclopedia of Human and Medical Virology. Boston: Academic Press. 5: 110-115

  20. Kew, M.C.(2003). Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepato Carcinogenesis. Liver international.  23(6):405—409

  21. Lawley, R. (2013). Aflatoxins: The science of safe food: Food safety watch. www.foodsafetywatch.org/factsheet/aflatoxins.

  22. Lewis, L., Onsongo, M., Njapau, H., Schurz – Rogers H., Luber, G., Kierzak, S. (2005). Aflatoxin contamination of commercial maize products during an outbreak of acute aflatoxicosis in eastern and central Kenya.  Environmental health perspective, 113:1763–1767.

  23. Li, F.Q., Li, Y.W., Luo, X.Y., Wang, Y.R., Luo, X.Y. (2009).”Natural occurrence of aflatoxin in Chinese peanut butter and sesame paste” Journal of agricultural and food chemistry, 57(9): 3519-3524.

  24. Liaw, Y. F., Brunetto, M. R., Hadziyannis, S. (2010). “The natural history of chronic HBV infection and geographical difference.” Antiviral therapy, 15: 25 – 33.

  25.  Lok, A., McMahon, B., (2007). Chronic hepatitis B infections. Journal of Hepatology, 45 (2): 507–39

  26. Liaw Y. F. (2011): Clinical utility of hepatitis B surface antigen, quantification in patients with hepatitis B: A review. Journal of hepatology. 53:2121-2159.

  27. Muthomi J. W., Njenga L. N., Gathumbi, J. K., Chemining’wa  G. W. (2009): The Occurrence of aflatoxins in maize and distribution of mycotoxin – producing fungi in Eastern Kenya. Journal of plant pathology. 8: 113-119.

  28. Muhia J. T., Straetmans M., Ibrahi A., Njau J., Muhanje O., Gurach A., Gikundi S., Mutonnga D., Tetteh C., Likimani S., Breiman R. F., Njenga K.,Lewis L. (2008). Aflatoxin levels in locally grown maize from Makueni District in Kenya. East african medical journal. Vol. 85 (7): 312 -316.

  29. Pearce, N., Richardi, L.(2014). Commentary: Three worlds collide. Berkson bias, Selection  bias,  and Collider bias. International journal of epidemiology 43(2): 521--524

  30. Redd, J.T., Baumbach, J., Kohn,W., Williams, I. (2009). “Patient to patient transmission of hepatitis B virus associated with Oral surgery” Journal of infectious diseases, 195(9):1311-1314.

  31. Rural 21, (2013). No chance for aflatoxins. International Journal for rural development;  http:www.rural21.com/English/news/details/article/no-chance-for-aflatoxin-0000656

  32. Schecsellman, J.J. (1982). Sample size determination in epidemiological studies. American Journal of Epidemiology. 115: 752-758.

  33. Scholl, F., Groopman , J.D.(2016). “Long term stability of human aflatoxin B1 albumin adducts assessed by Isotope-- dilution mass spectroscopy and HPLC-Fluoresence. Cancer epidemiological Biomarkers Preview. 17(6):1436--1439

  34. Sitia, G., Iannacone, M., Ruggeri, Z., Guidotti, L. ( 2007). HBV pathogenesis in animal models: recent advances on the role of platelets. Journal of Hepatology, 46 (4):719–26.

  35. Terrault, N., Roche, B., Samuel, D. (2005). "Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective". Liver Transpl. 11 (7): 716–32.

  36. Terrault, N.A., Bzowej, N.H., Chang K-M.(2016). AASLD guidelines for treatment of chronic hepatitis B infections. Journal of hepatology 63(1):261—283

  37. Turner, P.C., Dingley,K.H., Coxhead, J., Rusell, S., Garner, S. (1998). Detectable levels of  serum aflatoxin B1 albumin adduct in the United Kingdom population: Implications for AFB1 exposure in the United Kingdom. Cancer epidemiology, Biomarkers and Prevention. 7(5):441—7

  38. Westriech, D. (2012). Berkson Bias, Selection bias, and  missing data. Epidemiology, 23(1):159--164

  39. WHO, (2010). WHO guidelines on drawing blood: best practices in Phlebotomy. NLB: WB 381, 4:25-29

  40. WHO. (2018):  Aflatoxins: Risk assessments on aflatoxins undertaken by the joint FAO/WHO, expert committee on food additives. JECFA

  41. Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y. (2012). Sodium taurocholate co transporting polypeptide is a functional receptor for human hepatitis B and D virus. E Life 1: e00049.

bottom of page